	Цо	ward University	v			For Co	mmittee I	Use Only (Rev 11	/2017)
Proposal for I		ebrate Use in Re		ching or Tee	ting	Date Submitte			Received:
			scarch, rea	ichnig of Tes	ing	IACUC No.:		2000	
Form IACUC A: de novo continuat Effective 2011 the all submissions. S www.huiacuc.how as needed.	ions, and addend IACUC recomr See Instructions f	a or continuation nends and prefers for completing the	ns with signif s use of the I e IACUC Fo	ficant changes ACUC A For orms at	s. ms for	Type: D	e novo ontinuation Date ientific Me	Renewal 🔲 I n w/ significant ch re Reviewed	ite
Note: Incomplete in completing this BrownWalthall at	form call the IA marline.brownw	CUC Office at 20 althall@howard.	02 865 8353 . <u>edu</u> . The IA	or email <u>Mar</u> CUC Office		IBC NA	Pending Pending	_ ^^	
Address is IACUC						Final Approval			
Compliance, How			g (HURB-1),	1840 7 th Stre	et,	Expiration Date	e		
NW, Room 215, V	vashington, DC	20001.				No. Animals Ap	pproved T	his Period	
NOTE: You may ha	ve to click "View	and then "Edit" and	d/or "Enable (Content" to Inp	aut	USDA Categor	y:	C D D	E
Information.		and then Buit and		content to mp	at .	Notes:			
Principal Investig	gator (PI) and P	roposal Inform	ation						
First Name	Middle Initial	Last Name		Department			Building		Room No.
PI Phone No.		PI Email		PI's Technici	ian In Cl	narge	Technic	ian Phone No.	
Proposal Title									
J	From		To:						
Will proposal be p reviewed or student of Proposal for Labo	research proposals	s, prepare a researc	h plan followi	ing the outline i	in item IX	K. of Instructions			_ No _
Funding Source		t Start Date:				i uno proposui			
NIH 🗍 NS			r 🗌 (Spec	cify):					
Proposal Type:		newal Revis		yr De novo	Add	enda 🗌 or Coi	ntinuation	w Significa	nt Changes
Is proposal identic	al to a proposal	sent to other spor	nsor(s)? Y	les 🗌 No		If 'yes' enter I No.:	IACUC		
	NT I T. T 1	A 1 (C	1 1'		[D., 1., A1	1.055	(E	1
1.A. Animal Use Subjects (List thes							-		
research subjects.									
1.A.1. Animal Br PROGRAM. In									
be used as Resear	rch Subjects (Al	so list these und	ler 1.A.2.) a	nd (4) Numb	er of Of	fspring to be c	culled or	removed as not	suitable for
use as research s	v					S: Provide B	reeding p	rogram details	under the
Breeding Program	m Standard On	anoting Duogody							
4 6 70 11				_					
Age of Breeding	Onset/Retireme		i <mark>res Form (a</mark> Scheme (sele	ect one) Ide	entify Cu			eded Pups (if a	pplicable):**
Age of Breeding Female		nt Breeding S	Scheme (sele -1F) 🗆 Trios (1	ect one) Ide 1M+2F)	entify Cu Removal I	ulling Method by Killing: Method * to Protocol No.:	1:	eeded Pups (if a	pplicable):**

If donating unneeded animals to another protocol complete the Animal Transfer Form **

N	o. Breeders:	Male	Female	Estimated No. Pups to be Born	Estimated No. Pups to be Culled	Estimated No. of Pups to be Used for Research	TOTAL (Breeders and Research Offspring)
		0	0	0	0	0	0

Provide information regarding any genotype related morbidity or mortality or strain characteristics for breeding animals or their offspring that will necessitate special animal care or management.

1. A.2. Complete this section for animals to be used as research subjects. List each strain separately.

Under 'Year' check year of project for which you are asking approval. Complete the following for each breed or strain:

- **I. Row # 1:** Enter total number of animals requested (New) or approved for your project each year 1-5. The year number can be changed from 1 to 5 or 6 to 10, etc. In the last column of Row # 1 the total for all years will compute automatically.
- **I.** Row # 2. If this is not a New proposal enter additional animals requested under the appropriate year 1-5; if New enter zero. In last column of Row # 2 the total additional animals added for all years will compute automatically.
- **I. Row #3.** Enter the sum of Row #1 and Row #2 will compute automatically in Row #3.
- **1.** Row # 4: <u>If this is not a New proposal</u> enter number of animals used to date under the appropriate year to date. If New enter zero. In last column of Row # 4 the total number of animals used for all years will compute automatically.
- **I.** Row # 5: For each year 1-5 the number of animals left or remaining for use will compute automatically (subtracting Row # 4 from Row # 3). In last column of Row # 5 the total for all years will compute automatically.

II. 6. and 7: Enter the average number of animals (to be) housed simultaneously. III. 8. and 9: Enter average # of animal housing days.

I. Total Animals Per Year at Species 1 mouse	в	Animals f breed or train(s)	or All Yea C57BI		ed or Stra	in(Rodents)	II. Average Simultaneo HOW MAI TIME?		III. Average Days Per An AVERAGE HOUSED D	to BE
Total Animals Per Year for each species of animal [See instructions above (*).]	Year 1	Year2	Year 3	Year 4	Year 5	Total for Years 1-5	6. Current Approved (if Not New) or Requested (New)		8. Current Approved (if Not New) or Requested (New)	9. Change Request (linter 0 if New)
Indicate the year or 12- month approval period for which approval to add or use animals applies→									(seek)	
1. No. Approved Requested	50	50	0	0	0	100	40	0	20	0
2. Additional No. Requested	10	15	0	0	0	25				
 New Total (Add 1 + 2) 	60	65	0	Ó	0	125				
4. No. Used To Date	5	0	0	0	0	5	1			
5. No. Remaining for Use (Subtract 4 minus 3)	55	65	0	0	0	120	1			
INDICATE NUMBER OF AN REMAINING ANIMALS PRE within this 12 month approval j	VIOUSL									
For This Approval Period Only Enter Animal Numbers				of animals th approval		Number of n animals to be		arryover [from ; years (if applic		Total:
			50			15		44		120

The updated table should account for all animals (new, originally approved, used, added, carried over from previous years, etc.).

Each strain or breed must be listed separately.

Add a Supplemental Animal Numbers Form if needed.

I. Total Animals Per Year and Total Animals for All Years Per Breed or Strain (Rodents) II. Average No. Housed III. Average Housing Under Breed/Strain list each strain separately and enter entire strain genotype; add an Simultaneously **Days Per Animal** abbreviation if desired. Species 1 **Breed** or HOW MANY AT A AVERAGE TO BE Strain(s) TIME? **HOUSED DAILY?** 9. Change **Total Animals Per Year** Year2 Total for 6. Current 7. Change Year 1 Year 3 Year 4 Year 5 8. Current Approved (if Request Approved (if for each species of animal Years 1-5 Request (Enter 0 if Not New) or [See instructions above (*).] Not New) or (Enter 0 if Requested New) Requested New) (New) (New) Indicate the year or 12month approval period for which approval to add or use animals applies \rightarrow 1. No. Approved\Requested 0 0 0 0 0 0 0 0 0 0 2. Additional No. Requested 0 0 0 Numbers may be entered in Rows 1, 2 and 4 for Years 1 0 0 0 thru 5. 3. New Total (Add 1+2) 0 0 0 0 0 0 Numbers are automatically calculated in Rows 3 and 5. 4. No. Used To Date 0 0 0 0 0 0 If there is a delay in calculation after numbers are entered. 5. No. Remaining for Use 0 0 0 0 0 0 double click any number in Rows 1, 2 or 4 to the left of the (Subtract 4 minus 3) last number entered. INDICATE NUMBER OF ANIMALS YOU PLAN TO USE DURING OR WITHIN THIS 12-MONTH APPROVAL PERIOD (BE SURE TO ADD REMAINING ANIMALS PREVIOUSLY APPROVED IF YOU STILL PLAN TO USE THEM FOR THIS APPROVAL PERIOD) My request for or within this 12 month approval period is: The total will automatically calculate. If there is a delay in calculation double click any number to the left of "Total" For This Approval Period Only Year 1 request or number of New animals requested/ Carryover: You may add or choose not to add carryover Total: Enter Animal Numbers animals already approved for to be added this year animals not used in previous years to this 12 month this 12 month approval period approval period. 0 0 0 0 **Comments:**

I. Total Animals Per Year an Under Breed/Strain list each abbreviation if desired.			II. Average I Simultaneou		III. Average Housing Days Per Animal					
Species 2		reed or train(s)					HOW MAN TIME?	Y AT A	AVERAGE HOUSED D	-
Total Animals Per Year for each species of animal [See instructions above (*).]	Year 1	Year2	Year 3	Year 4	Year 5	Total for Years 1-5	6. Current Approved (if Not New) or Requested (New)	7. Change Request (Enter 0 if New)	8. Current Approved (if Not New) or Requested (New)	9. Change Request (Enter 0 if New)

Indicate the year or 12- month approval period for which approval to add or use animals applies→													
1. No. Approved Requested	0	0	0	0	0	0	0	0	0	0			
2. Additional No. Requested	0	0	0	0	0	0	-	be entered in R	lows 1, 2 and 4 f	or Years 1			
3. New Total (Add $1+2$)	0	0	0	0	0	0	thru 5.						
4. No. Used To Date 0 0 0 0 0 0 0 If there is a delay in calculation after numbers are ended													
5. No. Remaining for Use 0 0 0 0 0 0 0 0 double click any number in Rows 1, 2 or 4 to the left													
(Subtract 4 minus 3) last number entered.													
REMAINING ANIMALS PRE	INDICATE NUMBER OF ANIMALS YOU PLAN TO USE DURING OR WITHIN THIS 12-MONTH APPROVAL PERIOD (BE SURE TO ADD REMAINING ANIMALS PREVIOUSLY APPROVED IF YOU STILL PLAN TO USE THEM FOR THIS APPROVAL PERIOD) My request for or within this 12 month approval period is: The total will automatically calculate. If there is a delay in calculation double click any number to the left of "Total"												
For This Approval Period Only	1	equest or nu		-	als requeste			r choose not to ad		Total:			
Enter Animal Numbers	animals	already app	roved <mark>for</mark>		d this year		-	is years to this 12	2				
this 12 month approval period approval period.													
		0			0			0		0			
Comments:													

I. Total Animals Per Year an Under Breed/Strain list each s abbreviation if desired.				ents)	II. Average N Simultaneou		III. Average Days Per An						
Species 3		reed or train(s)						HOW MAN TIME?	Y AT A	AVERAGE HOUSED D			
Total Animals Per Year for each species of animal [See instructions above (*).]	Year 1	Year2	Year 3	Year 4	Year 5	Total fo Years 1		6. Current Approved (if Not New) or Requested (New)	7. Change Request (Enter 0 if New)	8. Current Approved (if Not New) or Requested (New)	9. Change Request (Enter 0 if New)		
ndicate the year or 12- nonth approval period for which approval to add or use animals applies→													
1. No. Approved\Requested 0 0 0 0 0 0 0 0 0 0 0 0													
2. Additional No. Requested 0 0 0 0 0 0 0 Numbers may be entered in Rows 1, 2 and 4 for													
3. New Total (Add $1+2$)	0	0	0	0	0	0		thru 5.			a 15		
4. No. Used To Date	0	0	0	0	0	0				dculated in Row on after number			
5. No. Remaining for Use (Subtract 4 minus 3)	0	0	0	0	0	0			ny number in R	ows 1, 2 or 4 to			
INDICATE NUMBER OF AN REMAINING ANIMALS PRE within this 12 month approval p	VIOUSLY	Y APPRO	VED IF Y	OU STILL	PLAN TC	USE TH	IEM F	FOR THIS APP	ROVAL PER	IOD) My reque	est for or		
For This Approval Period Only Enter Animal Numbers this 12 month approval period													
Comments:	I												

I. Total Animals Per Year an Under Breed/Strain list each abbreviation if desired.		II. Average I Simultaneou		III. Average Days Per An	0					
Species 4	reed or train(s)		HOW MAN TIME?	Y AT A	AVERAGE HOUSED D	-				
Total Animals Per Year for each species of animal [See instructions above (*).]	Year 1	Year2	Year 3	Year 4	Year 5	Total for Years 1-5	6. Current Approved (if Not New) or Requested (New)	7. Change Request (Enter 0 if New)	8. Current Approved (if Not New) or Requested (New)	9. Change Request (Enter 0 if New)

Indicate the year or 12- month approval period for which approval to add or use animals applies→	nonth approval period for □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □												
1. No. Approved Requested	0	0	0	0	0	0	0	0	0	0			
2. Additional No. Requested	0	0	0	0	0	0	•	be entered in R	Rows 1, 2 and 4 f	for Years 1			
3. New Total (Add $1+2$) 0 0 0 0 0 0 thru 5. Numbers are automatically calculated in Rows 3 and 5.													
4. No. Used To Date 0 0 0 0 0 0 0 0 0 0 If there is a delay in calculation after numbers are													
5. No. Remaining for Use 0 0 0 0 0 0 0 0 double click any number in Rows 1, 2 or 4 to the l													
(Subtract 4 minus 3) last number entered.													
REMAINING ANIMALS PRE	INDICATE NUMBER OF ANIMALS YOU PLAN TO USE DURING OR WITHIN THIS 12-MONTH APPROVAL PERIOD (BE SURE TO ADD REMAINING ANIMALS PREVIOUSLY APPROVED IF YOU STILL PLAN TO USE THEM FOR THIS APPROVAL PERIOD) My request for or within this 12 month approval period is: The total will automatically calculate. If there is a delay in calculation double click any number to the left of "Total"												
For This Approval Period Only	Year 1 re	equest or nu	umber of	New anim	als requeste	d/ Carryover	<mark>:</mark> You may add oi	r choose not to ac	dd carryover	Total:			
Enter Animal Numbers		already app		to be adde	d this year		ot used in previou	is years to this 12	2 month				
this 12 month approval period approval period.													
		0			0			0		0			
Comments:	•		Comments:										

for each species of animal [See instructions above (*).] Image: See instructions above (*).] Image	I. Total Animals Per Year ar Under Breed/Strain list each s abbreviation if desired.					Simultaneously Day								
for each species of animal [See instructions above (*).] Image: See instructions above (*).] Image	Species 5								Y AT A					
month approval period for which approval to add or use animals applies→ Image: Ima	for each species of animal	Year 1	Year2	Year 3	Year 4	Year 5		Approved (if Not New) or Requested	Request (Enter 0 if	Approved (if Not New) or Requested	9. Change Request (Enter 0 if New)			
2. Additional No. Requested 0 0 0 0 0 0 Numbers may be entered in Rows 1, 2 and 4 for Years thru 5. 3. New Total (Add 1 + 2) 0 0 0 0 0 0 0 4. No. Used To Date 0 0 0 0 0 0 0 0 5. No. Remaining for Use 0 0 0 0 0 0 0 0 0 (Subtract 4 minus 3) 0 <td colspan="14">month approval period for privation of the second second</td>	month approval period for privation of the second													
3. New Total (Add 1 + 2) 0 0 0 0 0 0 0 4. No. Used To Date 0	1. No. Approved\Requested	0	0	0	0	0	0	0	0	0	0			
S. New Total (Add 1 + 2) 0 </td <td>2. Additional No. Requested</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td>0</td> <td></td> <td>be entered in F</td> <td>Rows 1, 2 and 4 f</td> <td>or Years 1</td>	2. Additional No. Requested	0	0	0	0	0	0		be entered in F	Rows 1, 2 and 4 f	or Years 1			
4. No. Used To Date 0	3. New Total (Add $1+2$)	0	0	0	0	0	0				a 15			
5. No. Remaining for Use (Subtract 4 minus 3) 0 <td< td=""><td>4. No. Used To Date</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td>0</td><td></td><td></td><td></td><td></td></td<>	4. No. Used To Date	0	0	0	0	0	0							
REMAINING ANIMALS PREVIOUSLY APPROVED IF YOU STILL PLAN TO USE THEM FOR THIS APPROVAL PERIOD) My request for or within this 12 month approval period is: The total will automatically calculate. If there is a delay in calculation double click any number to the left of "Total" For This Approval Period Only Year 1 request or number of animals already approved for this 12 month approval period New animals requested/ to be added this year Carryover: You may add or choose not to add carryover animals not used in previous years to this 12 month approval period. Total 0 0 0 0 0 0	e	0	0	0	0	0	0	double click a	ny number in R					
Enter Animal Numbers animals already approved for this 12 month approval period to be added this year animals not used in previous years to this 12 month approval period. 0 0 0 0 0 0	REMAINING ANIMALS PRE	VIOUSLY	Y APPRO	VED IF Y	OU STILL	PLAN TO	USE THEM	FOR THIS API	PROVAL PER	IOD) My requ	est for or			
		animals	already app	roved for		1	animals	not used in previou		2	Total:			
Comments:	Comments:						<u> </u>							

I. Total Animals Per Year a Under Breed/Strain list each abbreviation if desired.			II. Average Housed Sin	e No. nultaneously	III. Average Days Per An					
Species 6		reed or train(s)					HOW MAN TIME?	NY AT A	AVERAGE HOUSED D	-
Total Animals Per Year for each species of animal [See instructions above (*).]	Total Animals Per YearYear 1Year 2for each species of animalYear 1Year 2					Total for Years 1-5	6. Current Approved (if Not New) or Requested (New)	7. Change Request (Enter 0 if New)	8. Current Approved (if Not New) or Requested (New)	9. Change Request (Enter 0 if New)

Indicate the year or 12- month approval period for which approval to add or use animals applies→	nth approval period for □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □											
1. No. Approved Requested	0	0	0	0	0	0	0	0	0	0		
2. Additional No. Requested	0	0	0	0	0	0		ay be entered in	Rows 1, 2 and 4	for Years 1		
3. New Total (Add 1+2)	0	0	0	0	0	0	thru 5.					
4. No. Used To Date 0 0 0 0 0 If there is a delay in calculation after numbers and the second s												
5. No. Remaining for Use 0 0 0 0 0 0 0 0 double click any number in Rows 1, 2 or 4 to the formula of the term of term												
(Subtract 4 minus 3) last number entered.												
REMAINING ANIMALS PRE	INDICATE NUMBER OF ANIMALS YOU PLAN TO USE DURING OR WITHIN THIS 12-MONTH APPROVAL PERIOD (BE SURE TO ADD REMAINING ANIMALS PREVIOUSLY APPROVED IF YOU STILL PLAN TO USE THEM FOR THIS APPROVAL PERIOD) My request for or within this 12 month approval period is: The total will automatically calculate. If there is a delay in calculation double click any number to the left of "Total"											
										Total:		
For This Approval Period Only Enter Animal Numbers — Year 1 request or number of animals already approved for this 12 month approval period												
		0			0			0		0		
Comments:	Comments:											

I. Total Animals Per Year a Under Breed/Strain list each abbreviation if desired.			· · · · ·	II. Average Housed Sin	e No. nultaneously	III. Average Days Per An						
Species 7	_	reed or train(s)					HOW MAI TIME?	NY AT A	AVERAGE HOUSED D	-		
Total Animals Per Year for each species of animal [See instructions above (*).]	Year 1	Year2	Year 3	Year 4	Year 5	Total for Years 1-5	6. Current Approved (if Not New) or Requested (New)	7. Change Request (Enter 0 if New)	8. Current Approved (if Not New) or Requested (New)	9. Change Request (Enter 0 if New)		
Indicate the year or 12- nonth approval period for □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □												
1. No. Approved\Requested	0	0	0	0	0	0	0	0	0	0		
2. Additional No. Requested	Rows 1, 2 and 4	for Years 1										
3. New Total (Add 1+2)	0	0	0	0	0	0	thru 5. Numbers er	automotically	calculated in Ro	wa 3 and 5		
4. No. Used To Date	0	0	0	0	0	0			ion after numbe			
5. No. Remaining for Use (Subtract 4 minus 3)	0	0	0	0	0	0	double click last number	any number in l entered.	Rows 1, 2 or 4 to	the left of the		
INDICATE NUMBER OF AN REMAINING ANIMALS PRE within this 12 month approval p	VIOUSL	Y APPRO	VED IF Y	OU STILL	PLAN TC	USE THEM F	OR THIS API	PROVAL PER	IOD) My reque	est for or		
For This Approval Period Only Enter Animal Numbers this 12 month approval period												
		0			0			0		0		
Comments:	•			-					• •			

					II. Average Housed Sin	e No. nultaneously	III. Average Days Per An	0		
Species 8		reed or train(s)					HOW MAN TIME?	NY AT A	AVERAGE HOUSED D	-
Total Animals Per Year for each species of animal [See instructions above (*).]	Year 1	Year2	Year 3	Year 4	Year 5	Total for Years 1-5	6. Current Approved (if Not New) or Requested (New)	7. Change Request (Enter 0 if New)	8. Current Approved (if Not New) or Requested (New)	9. Change Request (Enter 0 if New)

Indicate the year or 12- month approval period for which approval to add or use animals applies→											
1. No. Approved Requested	0	0	0	0	0		0	0	0	0	0
2. Additional No. Requested	0	0	0	0	0		0		ay be entered in	Rows 1, 2 and 4	for Years 1
3. New Total (Add 1+2)	0	0	0	0	0		0	thru 5.			2 15
4. No. Used To Date	0	0	0	0	0		0	Numbers are automatically calculated in Rows 3 and 5.			
5. No. Remaining for Use (Subtract 4 minus 3)	0	0	0	0	0		0	If there is a delay in calculation after numbers are entered, double click any number in Rows 1, 2 or 4 to the left of the last number entered.			
INDICATE NUMBER OF AN REMAINING ANIMALS PRE within this 12 month approval p	VIOUSL	Y APPRO	VED IF Y	OU STILL	PLAN TO	USE	E THEM FO	OR THIS APP	PROVAL PER	IOD) My requ	est for or
For This Approval Period Only Enter Animal Numbers	animals	equest or m already app nonth appro		for to be added this year			Carryover: You may add or choose not to add carryover animals not used in previous years to this 12 month approval period.			-	Total:
		0			0				0		0
Comments:				-						•	

Genetically Modified or Mutant Animals: Describe any phenotypic or behavioral or other life quality or life span altering consequences of the natural or induced mutation or genetic manipulations of the animals (include a profile of the life span, morbidity and mortality, etc.). Describe in detail any special care or monitoring animals will require. If genotyping is required describe in detail genotyping procedures.

Justification of Animal Use: Justify the use of animals vs. non-animal methods below.

Justification of Species and Strains (or Breeds). Justify the choice of species and strains (or breeds) below.

1.A.3. Field Studies (Section under revision)

1. B.1. Location of Animal Housing and Use (Check	or Enter Information below)	
Location of Animal Housing:		
Veterinary Services Just Hall	Other On Campus IACUC Approved Site 🗌 (Specify Bl	ldg, Room # Below)
Room # Room #		
1. B. 2. Location of Animal Use:		
Veterinary Services Just Hall	Other On Campus IACUC Approved Site [] (Specify B	Bldg, Room # Below)
Room # Room #		
1. B. 3. Describe transportation from site of animal hou	using to site of animal use if not in Veterinary Services or Jus	st Hall.
1. B. 4. Is authorization requested to hold animals outs	ide of IACUC approved housing more than 12 hours? Y	Yes 🗌 No 🗌
If 'yes', justify below.		
		Yes No
Outside Housing of Animals: Complete this part if ar	limals will be housed outside of HU:	
Institution Name:		
Institution Address:		
Institution Assurance No.		
Name of IACUC Chairperson of other institution	P	Phone No.

Has your proposal b	been approved by IACUC at the other institution?	Pending	Yes		No	
Is the other instituti	on AAALAC accredited?		Yes		No	
1.C. 2.Special Hou	sing /Care Requirements (Indicate any special housing, diet, light cycle, o	carcass disposal	require	ements)	
	hment and Social Housing Management: OLAW and AAALAC have place					
	ned as the system of animal environmental and social management that promotes sp plement enrichment through animal species group housing, positive interaction wit					
	caging accessories or toys, nesting material and nutritionally compatible food treat					
	st building and burrowing. And while enrichment items such as nesting material for					
	ly promotes species-specific behavior, other more complex enrichment paradigms i					
	r background biochemical and physiological parameters. This may unfavorably im be actively pursued for the benefit of the animal. With this as a background, Veter					
	tal enrichment (rodents - group housing, mice – nesting material, rats – PCV pipe of					
(cage toys f	or cats, ferrets and swine) food treats and group housing of compatible animals. R	odents may be pro	ovided i	onnutr	itive che	w toys
	searchers must decide whether to opt in or out of enrichment or specify restrictions					n, VS
	plement social housing of social animals unless prohibited or limited by you, the Pr					a fan
	y based rationale that pair or group housing will interfere with research objectives or s and provide justification for any restriction or limitation of enrichment or so					g 101.
enrichment		and insubility. All	,5 muit			
Species 1	I place no restrictions on enrichment for animals on my study as sum	marized				
	I place restrictions on my study as follows: Single housing (other					
	habitat enrichment items (nesting material or tunnels or huts)	s 📙 No non-nut	ritive	ood tr	eats	No
Second 2	nutritive food treats Other (specify):					
Species 2	I place no restrictions on enrichment for animals on my study as sum		1 \		T	
	I place restrictions on my study as follows: Single housing (other habitat enrichment items (nesting material or tunnels or huts) No toys					Ne
	nutritive food treats Other (specify):		Intive I	ood in		INO
Species 3	I place no restrictions on enrichment for animals on my study as sum	narized				
Species e	I place restrictions on my study as follows: Single housing (other		dams)		lo cage	
	habitat enrichment items (nesting material or tunnels or huts)					No
	nutritive food treats Other (specify):					
Species 4	I place no restrictions on enrichment for animals on my study as sum					
	I place restrictions on my study as follows: Single housing (other					
	enrichment items (nesting material or tunnels or huts) \square No toys \square No	non-nutritive fo	ood tre	ats 📋	No nutr	itive
Spacing 5	food treats Other (specify):	nomized				
Species 5	I place no restrictions on enrichment for animals on my study as summ I place restrictions on my study as follows: Single housing (other		dame)		lo cage	hahitat
	enrichment items (nesting material or tunnels or huts) \square No toys \square No					
	food treats Other (specify):			·		
Species 6	I place no restrictions on enrichment for animals on my study as sum	narized				
	I place restrictions on my study as follows: Single housing (other	er than pregnant				
	enrichment items (nesting material or tunnels or huts) 🗌 No toys 🗌 No	non-nutritive fo	ood tre	ats	No nutr	itive
a • =	food treats Other (specify):	· •				
Species 7	I place no restrictions on enrichment for animals on my study as sum				T	h = h : (- (
	I place restrictions on my study as follows: Single housing (other enrichment items (nesting material or tunnels or huts) No toys No					
	food treats Other (specify):		ou ne	110 <u> </u>	ino nuti	11110
Species 8	I place no restrictions on enrichment for animals on my study as sum	narized				
Species 6	☐ I place restrictions on my study as follows: ☐ Single housing (other		dams)		lo cage	habitat
	enrichment items (nesting material or tunnels or huts) 🗌 No toys 🗌 No					
	food treats Other (specify):					
Provide Justification	n for any restriction in enrichment for each species listed OR request additi	onal enrichment	desire	d for y	our anii	nals.:
	f Hazardous Agents/Materials in Animals: Are agents/materials to be use	ed in animals cla	ssified	Y	es 🗌 1	No 🗌
as hazardous?	If Was shack all that apply below.					
Recomb. DNA	If 'Yes' check all that apply below: Radioisotope Carcinogen Infectious Agent Select Agent	ent 🗌 🗍 Touis 1)mac/C	homic		Other [
Kecomo. DINA		ent 🔄 🛛 Toxic I	лug/С	nennca	ai 🗀	Juner

If 'No' go to 1.E.	If 'Yes' check all that	apply below:					
Recomb. DNA	Radioisotope	Carcinogen	Infectious Agent	Select Agent	Toxic Drug/Cher	mical 🗆	Other
Recomb. DNARadioisotopeCarcinogenInfectious AgentSelFor biological agents select the Animal Biosafety Level (ABSL) for this protocol:					ABSL2	ABSL3	

Provide the identification for each agent (s) for each category checked above and complete the IACUC Form for Use of Hazardous Materials/Agents in
Animals.

Note: A "Yes" response to 1D requires submission of an application or receipt of an exemption from the appropriate Safety Committee(s)
[Institutional Biosafety Committee (IBC) or Radiation Safety Committee (RSC)]. It is the responsibility of the Principal Investigator to assure that
applications are submitted to the appropriate safety committee for work to be carried out under this proposal It is also the responsibility of the Principal Investigator to assure
that copies of the IBC and RSC Committee Letter of Approval are submitted to the IACUC.

Safety Committee (SC) Approval Status

IBC:	Approved on	Not Approved	Pending	RSC:	Approved on	Not Approved		
1. E. Ani	mal Handling/Anim	al Surgical Trainin	ng and Experie	ence: L	ist all persons (inclue	ding Principal Investiga	tor, students, and	
research a	nd lab technicians) w	ho will handle the a	nimals and per	form ex	perimental technique	es.		

	ne Training, References, Experienc			
	uide for the Care and Use of Laborate			Yes No
	ersion) is available in my laboratory.			
	ww.huiacuc.howard.edu. If your resp	oonse is 'No' to any it	em the IACUC at 202	
865 8353 and request copies.				
Online Training and Experience:				
Animal Handlers		Completed CITI	Online Training and	Experience With
		Certification		Relevant Species
Last Name, First Name		Yes	No	(yrs)
Surgical Experience: Experience	with surgical procedures to be used	l in this proposal or e	experience relevant to t	his proposal
Animal Surgeon(s)	Experience with Surgical Procedu			Experience With
0 ()		1	1	Surgical Procedure
Last Name, First Name	Yes		No	(yrs)
	\square			
			\Box	
	\square			
Training of inexperienced individu	uals and maintenance of formal tra	ining records: Indica	ate what provisions will	be made to instruct
and train project personnel who have				
be maintained to confirm training (1)			e of training and location	n of training)
be maintained to confirm training (in	ndividual trained, trainer, procedure tr		e of training and location	n of training)

Collaborators: Provide the name(s) and experience of collaborators for this project and provide a letter from each collaborator affirming their role and agreement to collaborate on the project.

1. F Project Purpose, Hypothesis and Benefit: Please use lay person terminology since nonscientists may access this information. Avoid or define first use acronyms. **Provide adequate detail so that the general public would understand what is being studied, why the**

particular animal model was selected and how and why animals will be used. Also indicate what outcomes are expected to be	
achieved and what the justification is in terms of benefits of the research.	
Purpose	

Hypothesis	(Re sure to	include o	lescription	of animal	model an	d applicability	y for use in this	nronosal
riypoutesis	(DC Suit to	menuae c	resemption	or annual	mouel an	u applicating	y for use in this	proposal.

Benefits

Progress Report: If this is **not a new proposal** provide a progress report below or in the supplemental section at the end of this form.

2. A. Description of Animal Use: Check ALL that apply.

Behavior Study (Describe in 2G)	No Surgery	Unalleviated Pain, Stress or Distress (Justify*)	
Restraint >15 min/day(See 2B)	Nonsurvival Surgery (acute)	In Vivo rDNA (Biosafey Approval Required)	
Food Deprivation (Justify*)	Minor Survival Surgery	Mouse Ascites Model (Justification Needed*)	
Water Deprivation (Justify*)	Major Survival Surgery	Infectious Disease – Animal Pathogen	
Pain Study(Justify*)	Multiple Survival Surgery(Same animal)*	Infectious Disease- Human and Animal Pathogen	
Immunization Study	Sacrifice for Tissue Collection Only	Metabolic Disease	
Death as Endpoint (LD50, etc*.)	Environmental Manipulation (light, etc.)	Tumor Study (Define Size Limits, etc.)	
Paralytic Agent Use (Justify*)	Drug Efficacy/Toxicity Study	Toe Clip ID of Neonatal Mice (Justify*)	
GLP Study	Dogs, Cats or Nonhuman Primates	Endangered Species (Justify*)	
Device Evaluation	Rodent Breeding (Describe # needed)	Pregnant Dam Ordered: Request Short Quarantine	
Trauma Study (Justify*)	Field Study (attach copies of permits)	Genotyping Required (Fully describe in 2G)	
Severe Stress/Distress(*Justify)	Substance of Abuse Study		

*Provide additional information or justification for items checked that require a justification:

2. B. Restraint: This refers to restraint of a conscious animal that exceeds 15 minutes a day (not to unconscious anesthetized animal). Will animals be restrained for longer than 15 minutes on any day? \Box No -> If 'No' go to 2C \Box Yes -> If 'Yes' justify below: If restraint exceeds 15 minutes a day, identify restraint device, justify use, indicate restraint time per session and whether animals will be acclimated to restraint.

Estimate level of	pain, stress and	/or distress ex	perienced by a	nimal due to restraint:
\Box (none) 0	1	2	3	\Box 4 (severe)

2. C. Blood Collection: Indicate anatomical site, frequency, and volume withdrawn per collection time. Refer to IACUC Guidelines for collection limits. A sedative or anesthetic agent is required for retro-orbital sinus or intra-cardial collection: Provide agent and dosage information below.

2. D. Surgical Procedures: See VIII of Instructions to estimate level of pain, stress and/or distress (P, S, D).									
OR	Animal			Identify each	Actual P,S,D Level Experienced by the Animal: (none)				
Location				operative procedure	0,1,2,3,4 (severe)				
	Species	Sex No. Animals			and number of times	Operative		Post-Op	
	\Strain		Upcoming	All years	it will be performed on a single animal.	PSD Level	Duration	PSD Level	Duration
			12 months		on a single annial.				
2. E. Non-Surgical Procedures: See VIII of <i>Instructions</i> to estimate level of P,S,D. Important Note: Researchers employing disease									
production models, tumor studies or immunization note that while the injection of a pathogen, neoplastic cells or adjuvant may be almost									
painless, the postprocedural consequences of disease (pneumonia, neurological disorders, progressive dehydration and debilitation,									
malignanc	y, etc.) or inflam	nmation a	t the site of in	njection (pos	t Freunds abscessation	n, ulceration) r	nay be moder	ate to severe.	
Procedure	e Animal			Identify procedure	Actual P,S,D Level Experienced by the Animal:			Animal:	
Room				and number of times	(none) 0,1,2,3,4 (severe)				
Location	Species	Sex	No. Ai	nimals	it will be performed on a single animal	Procedural		Post-Procedural	
	-	Sex			on a single annual	PSD Level	Duration	PSD Level	Duration
	\Strain		Upcoming 12 months	All years		I SD Level	Duration	1 SD Level	Duration

a 0 0 a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a a						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stand stand of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stand stand of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stand stand of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stand stand of the stand stand stand of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stand stand of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stand stand of the stand sta						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stan						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stan						
physiological impairment? If 'yes', describe and justify below. Image: Content of the stand stan						
the start of research use to cuthanasia. An overview of procedures can be presented here in a chronological order and surgical and nonsurgical details can be provided pro or in an attached standard operating procedure document (SOP). If SOPs are used to provide procedural details each SOP must be listed here by title. In either case all procedures, drug use (agent, route, dosage, volume, etc.) must be provided. Provide a flow chart from beginning to end that that illustrates all of the procedures groups of animal will undergo. Make sure that animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study; Yes □ No □ Will PAD be given? Yes □ No □ If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administration, frequency of administration, and experimental phase when drug will be given (e.g. 30) minutes prior to performing surgical or nonsurgical procedure. Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical						
the start of research use to cuthanasia. An overview of precedures can be presented here in a chronological order and surgical and nonsurgical details can be provided procedure of an attached standard operating procedure document (SOP). If SOPs are used to provide procedural details each SOP must be listed here by title. In either case all procedures, drug use (agent, route, dosage, volume, etc.) must be provided. Provide a flow chart from beginning to end that that illustrates all of the procedures groups of animal will undergo. Make sure that animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study. Yes □ No □ Will PAD be given? Yes □ No □ If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administration, frequency of administration, and experimental phase when drug will be given (e.g. 30) minutes prior to performing surgical or nonsurgical procedure. Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgic						
ionsurgical details can be provided here or in an attached standard operating procedure document (SOP). If SOPs are used to provide procedural details each SOP must be listed here by title. In either case all procedures, drug use (agent, route, dosage, volume, etc.) must be provided. Provide a flow chart from beginning to end that that illustrates all of the procedures groups of animal will undergo. Make sure that animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes □ No □ Will PAD be given? Yes □ No □ If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D						
provide procedural details each SOP must be listed here by title. In either case all procedures, drug use (agent, route, dosage, volume, etc.) must be provided. Provide a flow chart from beginning to end that that illustrates all of the procedures groups of animal will undergo. Make sure that animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will PAD be given? Yes No If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \Preprocedural Drugs Used (Ex: Acceptomazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be a						
volume, etc.) must be provided. Provide a flow chart from beginning to end that that illustrates all of the procedures groups of animal will undergo. Make sure that animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes \Box No \Box Will PAD be given? Yes \Box No \Box If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. Averse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of Adverse Effects(AE):						
Provide a flow chart from beginning to end that that illustrates all of the procedures groups of animal use for any group of animals from start to finish. This Flow Chart or Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes □ No □ Will PAD be given? Yes □ No □ If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of Adv						
animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes No Will PAD be given? Yes No Hit response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug ame, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g., 30 minutes prior to performing surgical or nonsurgical procedure). Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g., 1f there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of Adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of Adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention for not preventing/minimizing AE (if applicable)						
animal numbers agree with those listed in Table 1A2. Flow charts should reflect the time line of animal use for any group of animals from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes No Will PAD be given? Yes No Hit response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug ame, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g., 30 minutes prior to performing surgical or nonsurgical procedure). Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g., 1f there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of Adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of Adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention for not preventing/minimizing AE (if applicable)						
from start to finish. This Flow Chart or Table can also be inserted under Supplemental Information at the end of the form. 2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes □ No □ Will PAD be given? Yes □ No □ If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Provide justification for not preventing/minimizing AE (if applicable)						
2. H. Pain or Distress Alleviating Drugs (analgesics, sedatives, tranquilizers, etc.) Administration (PAD): Will animals experience pain and/or stress and/or distress in this study: Yes □ No □ Will PAD be given? Yes □ No □ If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g., 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Provide justification for not preventing/minimizing AE (if applicable)						
Will animals experience pain and/or stress and/or distress in this study: Yes No Will PAD be given? Yes No If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Provide justification for not preventing/minimizing AE (if applicable)						
Will animals experience pain and/or stress and/or distress in this study: Yes No Will PAD be given? Yes No If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Provide justification for not preventing/minimizing AE (if applicable)						
If the response is 'Yes' that animals will experience pain and/or stress and/or distress (PAD) and they will not be given PAD alleviating drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine <u>prior to</u> obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
drugs provide justification for not administering PAD: Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine <u>prior to</u> obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
 Presurgical \ Preprocedural Drugs Used (Ex: Acepromazine prior to obtaining blood from the ear veins of rabbits, pre-emptive analgesia, etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable) 						
etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
etc.) Provide drug name, dosage, route od administration, frequency of administration, and experimental phase when drug will be given (e.g. 30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
30 minutes prior to performing surgical or nonsurgical procedure.) Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Surgical or Procedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
and dosages of drugs used to relieve pain, stress or distress. Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Postsurgical or Postprocedural Drugs Used: For each procedure listed (under 2.D and 2. E.) provide names, routes, frequency of administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
administration and dosages of drugs used to relieve pain, stress or distress and experimental phase when drug will be given (e.g. If there is evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
evidence of pain, 48 hrs post-op) 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
 2. I. Assessment, Prevention and Minimization of Adverse Effects(AE): Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable) 						
Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Adverse Effects (AE): List potential adverse effects of each surgical or nonsurgical procedure. Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Detection of AE: Describe how AE will be assessed. Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Prevention and Minimization of AE: Describe how AE will be prevented (e.g., analgesics, euthanasia, transfusion, acclimation to restraint) Provide justification for not preventing/minimizing AE (if applicable)						
Provide justification for not preventing/minimizing AE (if applicable)						
Provide justification for not preventing/minimizing AE (if applicable)						
2. J. Alternatives Search for USDA Covered Species: Stipulate USDA Study Category (C, D or E) potential for any group of animals that						
2. J. Alternatives Search for USDA Covered Species: Supulate USDA Study Category (C, D or E) potential for any group of animals that						
may experience pain, stress or distress during this approval year. *Cotagery C: No pain/distress and no use of pain reliaving drugs (routing procedures, injections and blood sampling)						
*Category C: No pain/distress and no use of pain-relieving drugs (routine procedures, injections and blood sampling) **Category D: Pain/distress for which appropriate anesthetic, analgesic, or tranquilizing drugs are used						
***Category E: Pain/distress for which the use of appropriate anesthetic, analgesic, or tranquilizing drugs are withheld due to adverse						
effects on procedures, results or interpretations.						
effects on procedures, results or interpretations.						

Alternatives Search for USDA Covered Species See relevant sections of the IACUC Guidelines for Investigator Research or Teaching for information on completing this section. Attach search and retain a copy for your records a conducting and adequate literature search one is looking for Reductions and/or Refinements and/or Replacements a R's (Reduction, Refinement and Replacement): Incorporation of Procedures for Reduction, Refinement and/or I Definitions: Reduction: Minimize the number of animals used. Refinement: Employ techniques that reduce pair Replacement: Substitute animal with nonanimal or animals that are less sentient or lower on the phylogenetic scall Please note that USDA-APHIS considers the statement, "No alternatives found" (or equivocal statement) to a alternatives search was, in a majority of cases, inadequately carried out. DO NOT SKIP ANY SECTION.	until project ends. In s defined below: Three Replacement: in and distress. e.
Databases Searched: Current Research Information Service Medline BIOSIS Previews EMBASE Agricola Pascal Toxline Altweb SCOPUS Other (specify):	CAB Extracts
Enter years covered in search (such as 2001 to 2011, etc.).	
Enter key words used and search strategies	
Other Sources Consulted	
Conclusions: Indicate the number of alternatives found and indicate why they were or were not applicable to you "None or No alternatives were found" is not generally viewed as an acceptable response. Indicate instances where a statistical or the statisti	nerein all or some of the
3. Justification of Animal Numbers (All Years)	
3.A. Define the groups of animals and number of animals in each group. Include a description of the statistical anal to answer each of your hypotheses (chi-square, t-tests, correlations, logistic regression, linear regression, etc.). The for all the groups should reflect the number of animals requested at the end of each table under 1.A. (Animal Use N	total number of animals
3.B. Justify the number of animals. Include the statistical assumptions you made to estimate the sample size needed	to answer each of your
hypotheses (alpha and beta type errors, one-sided or two-sided tests, power analyses, expected standard deviation of expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to est quantity or change (Δ), describe the desired level of precision to be achieved (e.g., "We wish to estimate the propor gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are r justification for the number of animals required in order to meet those objectives.	e size estimates are based timate a statistical tion of mice expressing
expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to est quantity or change (Δ), describe the desired level of precision to be achieved (e.g., "We wish to estimate the propor gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are r justification for the number of animals required in order to meet those objectives.	e size estimates are based timate a statistical tion of mice expressing non-statistical, provide a
expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to estimate the desired level of precision to be achieved (e.g., "We wish to estimate the proportion gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are n	e size estimates are based timate a statistical tion of mice expressing
expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to est quantity or change (Δ), describe the desired level of precision to be achieved (e.g., "We wish to estimate the propor gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are r justification for the number of animals required in order to meet those objectives.	e size estimates are based timate a statistical tion of mice expressing non-statistical, provide a
 expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to estimate the desired level of precision to be achieved (e.g., "We wish to estimate the proportion gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are rejustification for the number of animals required in order to meet those objectives. 3. C.1. Did you use a sample size software program? If yes, name the software program below. 	e size estimates are based timate a statistical tion of mice expressing non-statistical, provide a
 expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to est quantity or change (A), describe the desired level of precision to be achieved (e.g., "We wish to estimate the propor gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are rejustification for the number of animals required in order to meet those objectives. 3. C.1. Did you use a sample size software program? If yes, name the software program below. 3. C.2. Did a statistician assist you with your sample size estimates? If yes, name the statistician below. 4. Euthanasia Method: If applicable list drug, dose and route: ****In all cases indicate a primary means 	e size estimates are based timate a statistical tion of mice expressing non-statistical, provide a
 expected differences between groups or expected strength of the association). Include the statistical test your sample on (chi-square [Independent or goodness of fit], t-tests, correlations, ANOVA etc.). If your study objective is to est quantity or change (Δ), describe the desired level of precision to be achieved (e.g., "We wish to estimate the propor gene XYZ +/10, where the trait expression probability is expected to be about .50."). If the study objectives are rejustification for the number of animals required in order to meet those objectives. 3. C.1. Did you use a sample size software program? If yes, name the software program below. 3.C.2. Did a statistician assist you with your sample size estimates? If yes, name the statistician below. 	e size estimates are based timate a statistical tion of mice expressing non-statistical, provide a

Decapitation or cervical dislocation performed without sedation must be scientifically justified below. It is the responsibility of the PI to ensure that decapitation or cervical dislocation is performed by properly trained personnel. The use of carbon dioxide narcosis for rodent euthanasia requires compliance with current American Veterinary Medical Association Guidelines (with a displacement rate of 30% per minute and euthanasia in the home cage.).

Supplemental Information: Additional information may be entered or pasted below as required. Be sure to identify topic clearly. Example: the literature search.

I certify that this form is completed truthfully, that I and all persons who handle animals on this project are or will be appropriately trained, that the IACUC will be notified before any changes are made in animal use or care, that this study will be conducted humanely in accordance with University and applicable federal regulations, and that a reasonable good-faith effort was made to assure that the proposal activities do not unnecessarily duplicate previous experiments. Applicable IACUC guidelines will be followed.

FOR IACUC USE ONLY

IACUC Safety Form for In vivo Use of Hazardous Materials/Agents in Animals

Submit this Form ONLY if using hazardous agents or materials. It must also be reviewed and approved by the relevant Safety Committee. Enter IACUC Protocol Number (if available) and Proposal Title Below:

1. Identify hazardous material of agent (biological, chemical, radioactive, other)

2. For biological agents indicate the Biosafety Level (BSL 1,2 or 3); for rDNA agents indicate the Risk Group (RG 1, 2 or 3):

3. Indicate whether the agent(s) pose(s) a safety hazard to humans, animals, both or the environment. Describe each agent listed under No. 1 separately.

Complete the following section in sufficient detail for the committee to render a sound judgment. Failure to provide relevant information may delay approval and may constitute a serious breach of professional behavior. Attach an MSDS if available.
 Source(s) of Exposure: <u>Confine response to issues related to in vivo use. (e.g. Stock or dispensed material, animal breath, dander, fur, excrement or secretions, caging or research equipment, hood surface, aerosolized materials from centrifugation, sonication, stirring, mixing or other manipulation in the vivarium, etc.).
</u>

4.b. Assessment of the Risk: Source(s) of Exposure: <u>Confine response to issues related to in vivo use. (e.g. Does inoculation of</u> <u>material pose a risk, transport of agent to or from vivarium? Does handling\contact with the animal or bedding pose a risk and how long, etc.)</u> For biological agents follow BMBL risk assessment procedures, for chemicals base assessment on the MSDS, for recombinant DNA agents follow the NIH Guidelines for use of Recombinant DNA in research, for radioactive compounds follow RSC guidelines.

4.c. Control or Minimization of the Risks Cited under 4.b.: <u>Confine response to issues related to in vivo use. (e.g. Engineering controls, personal protective equipment (PPE), handling and secondary containment of stock material, storage, decontamination methods and <u>disposal</u>): Control must be consistent with federal, local and University regulations, requirements or guidelines.</u>

4.d. If medical screening or testing and health surveillance procedures have been recommended or are required briefly describe procedures below.

4.e. Indicate means of decontamination of agent in case of a spill or accidental release. Method must comply with Safety Committee and federal regulatory requirements.

4.f. Indicate training (including seminars to be given for research and /or VS staffs if required) /advising/supervision of research staff.

4.g. Written Warnings/Information (e.g. MSDS, BSL, RG, etc.): Provide a mock-up of the written warnings/information that must appear on the vivarium room door for protection of humans and or animals.

I affirm by my signature that the above information is true and complete.

Type or Print Name

Principal Investigator Signature

Date